Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as…

Continue ReadingAllogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
Read more about the article ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Continue ReadingALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute ; Astera Cancer Care, Part of the OneOncology Network; and…

Continue ReadingAllogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)